Taking people in Saudi ArabiaNo phase
Short-term Treatment Satisfaction in Hidradenitis Suppurativa Patients Initiated on Cosentyx in Routine Clinical Practice in Saudi Arabia
Key facts
- Who runs it
- Novartis Pharmaceuticals
- Where
- Jeddah and Riyadh, Saudi ArabiaSee the 2 sites
- Trial code
- Status
- Recruiting
- People taking part
- 77 people, planned
- Started
- 10 Mar 2025
- Planned end
- 30 Sept 2026
- Type of study
- Observational
- Treatments tested
- Secukinmab
- Record updated
- 30 December 2025
Who can take part
- Age
- 18 years to 99 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Male or Female adult patients ≥18 years of age at the time of data collection
- Patient with a confirmed diagnosis of active moderate to severe HS
- Secukinumab naive patients (first dose to coincide within one month of the signature of the informed consent) as per locally approved label
- Patients can be using antibiotics or have undergone surgery as per routine clinical practice
- Patients agree to sign an informed consent form (ICF) to be able to complete the questionnaires
Who cannot take part
- A history of off-label indication uses of biological treatment or JAK inhibitor
- Patients not fulfilling any of the above-mentioned inclusion criteria
- Patient's refusal to be included in the study or refusal to sign the ICF
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 99 years old?
Where in Saudi Arabia
- JeddahHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
- RiyadhHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
About the trial
What the trial wants to find out
This study aims to assess the treatment satisfaction of HS patients newly started on secukinumab in Saudi Arabia, in terms of patient reported convenience, perceived safety, perceived effectiveness and global treatment satisfaction as measured by the treatment satisfaction questionnaire for medication (TSQM) at week 24 among moderate to severe HS patients.
The group in the trial
- Secukinumab
Patients who are newly initiated on Secukinumab
Treatment: Secukinmab
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Survey Assessing Prospective Patient's Short-term Treatment Satisfaction and Quality of Life in Patients With Hidradenitis Suppurativa Initiated on Cosentyx (Secukinumab) in Routine Clinical Practice in Saudi Arabia: ILLUMINATE-SA
- Fit questions
- Built from NCT06785779, who can take part
- Record updated
- 30 December 2025